the drug has undergone a phase ii evaluation as first-line therapy for breast cancer however this study found no evidence to support further investigation. phase ii testing against persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas was also unsuccessful. two phase ii clinical trials for thyroid cancer showed promising results.